Our CEO Jeremy Skillington, PhD presented “p38 MAPK inhibition – novel method to prevent CRS and enable safer administration of cell therapies” at Cell & Gene Therapy International Europe in Dublin last week. We were delighted to see such high attendance at Poolbeg Pharma plc Pharma’s session and the excitement shared about the potential of POLB 001 to address cancer immunotherapy-induced CRS. #POLB #Dublin #CellTherapy #Presentation
Poolbeg Pharma plc’s Post
More Relevant Posts
-
It's nice to realize that my review on the therapeutic use of engineered myeloid cells in cancer therapy has been recognized by the readers as one of the top 10 articles published by Cancer Gene Therapy in 2023! #NCH
-
Day 2 of our Oncology Insights event! Today, explore recent advancements in viral-vector cell and gene therapy technologies and how to leverage them for the successful development of personalized cancer therapies. Save my spot: https://hubs.ly/Q02vqK620 #CancerResearch #OncologyResearch #PrecisionMedicine #Genomics #GeneTherapy #CellTherapy
-
-
Embrace the era of certainty with Digital PCR! Elevate your research with the precision and sensitivity of dPCR for higher reproducibility across various therapeutic areas like Cell and Gene Therapy, Oncology, Monoclonal Antibodies, Vaccine development and more. Connect with us to learn more about how dPCR can help you with your next breakthrough discovery: https://hubs.ly/Q02Gn_-00 #ClinicalResearch #Genomics #DigitalPCR
-
-
Dive into innovation at TIDES 2024! Join us as we unveil groundbreaking insights in our breakfast spotlight presentation "Harnessing RNA to Simplify and Advance Gene Therapy" and our two posters, "Neoantigen vaccines: A promising cancer therapy" and "Integrated novel IVT RNA platforms to accelerate research and therapeutics development." Don't miss the chance to connect with our team! #TIDES2024 #oligonucletoide #peptide #genomeediting #mRNA
-
-
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer: https://lnkd.in/g98Pra2a
-
-
Dive into innovation at TIDES 2024! Join us as we unveil groundbreaking insights in our breakfast spotlight presentation "Harnessing RNA to Simplify and Advance Gene Therapy" and our two posters, "Neoantigen vaccines: A promising cancer therapy" and "Integrated novel IVT RNA platforms to accelerate research and therapeutics development." Don't miss the chance to connect with our team! #TIDES2024 #oligonucletoide #peptide #genomeediting #mRNA
-
-
The latest edition of The Dose covers the American Society of Hematology's 2024 Annual Meeting, highlighting the most impactful results presented during the recent conference. We review pre-clinical evidence supporting a novel ultrasound-mediated gene delivery mechanism, Phase 3 trial results for a novel gene therapy treating sickle cell disease, and the implications of Merck's presentations on trials spanning its robust hematology portfolio. Additionally, we explore efforts from Johnson & Johnson, BeiGene, and Eli Lilly to expand their footprint in hematology, with the latest results from clinical trials evaluating new applications for their existing treatments. #ASH2024 #Hematology #HealthcareInnovation #AmericanSocietyofHematology #OncologyResearch #AryaConsultingPartners #TeamArya
-
Radioresistance-related gene signatures identified by transcriptomics characterize the prognosis and immune landscape of pancreatic cancer patients https://lnkd.in/eQ9wztkE 🧪 @BioMedCentral #CancerResearch
-
-
The FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for patients with advanced pancreatic cancer harboring an NRG1 gene fusion. This news is especially exciting given it's the first systemic therapy of its kind for this gene group. For a disease with a survival rate of just 13%, this news represents more than just a treatment; it's a step toward giving patients more time and a better quality of life, while underscoring the importance of continued investment in bold solutions for this disease. Read more: https://bit.ly/4fu5BZn
-
-
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer: https://ow.ly/JCp650UrR2h
-
